12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest

Clinical Ethics, Patient Advocacy & Conflicts of Interest

Why this is scored content: The BCACP Examination Content Outline names Ethics and Patient Advocacy as sub-topic 2A3, sitting inside 2A Quality of Care in the Professional Practice domain. Candidates routinely treat ethics as soft background material and skip it. It is blueprint content, and because Domain 2 carries only ~26 scored items, a handful of ethics questions represents a meaningful share of that domain.

Ambulatory practice generates a distinctive set of ethical problems. Unlike inpatient care, the ambulatory pharmacist manages a longitudinal relationship with a patient who goes home and makes their own choices, faces real cost tradeoffs, and may decline what the evidence recommends. The exam tests whether you can reason through those situations rather than simply recite guidelines.

1. The Four Principles Framework

Most ambulatory ethics items resolve against the four-principles model:

When Principles Collide

The exam favors items where two principles conflict. The governing rule: a decisionally capable, adequately informed patient's refusal of therapy is respected, even when the clinician judges the refusal harmful. The pharmacist's obligation is to ensure the refusal is genuinely informed — that the patient understands the consequences, that reversible barriers (cost, fear of injections, dosing complexity, prior adverse experience) have been explored, and that the door stays open for reconsideration. Overriding a capable refusal is paternalism, not beneficence.

A frequent distractor pattern presents "escalate to the physician to convince the patient" or "contact a family member" as the correct action. Neither is right when the patient has capacity and has not authorized the disclosure — the second additionally breaches confidentiality.

2. Decision-Making Capacity vs. Legal Competence

These are distinct, and the exam tests the distinction.

• Competence is a legal determination made by a court. Clinicians do not declare patients incompetent.
• Capacity is a clinical determination that any qualified clinician, including a pharmacist within their scope, can assess.

The Four Abilities of Capacity

A patient has capacity for a given decision if they can:

1. Understand the relevant information (what the therapy is, what it does).
2. Appreciate how the information applies to their own situation.
3. Reason about the options, weighing risks and benefits.
4. Express a choice consistently.

Capacity is decision-specific and can fluctuate. A patient with mild cognitive impairment may lack capacity to weigh a complex anticoagulation decision yet retain capacity to consent to an influenza vaccine. Capacity is also not determined by whether the clinician agrees with the choice — an unpopular decision is not evidence of incapacity.

Surrogate Decision-Making Hierarchy

When a patient lacks capacity, decisions follow this order of preference:

1. Advance directive / living will — the patient's own previously expressed instructions.
2. Healthcare power of attorney or healthcare proxy — the agent the patient designated.
3. Default surrogate under state law (commonly spouse, then adult children, then parents, then siblings).

Surrogates apply substituted judgment — deciding as the patient would have decided — and fall back on a best-interest standard only when the patient's prior wishes are unknown.

3. Informed Consent in Ambulatory Pharmacy

Valid informed consent requires disclosure of the nature of the intervention, its risks and benefits, reasonable alternatives (including doing nothing), and confirmation of understanding. In ambulatory pharmacy this arises with vaccine administration, point-of-care testing, telehealth encounters, enrollment in REMS programs, and participation in research or quality-improvement registries.

• Teach-back is the verification step. Asking "do you have any questions?" does not establish understanding; asking the patient to explain the plan in their own words does.
• Language access is a legal duty, not a courtesy. Qualified interpreter services must be offered; using a family member — especially a minor — as interpreter is inappropriate except in emergencies.
• Emancipated and mature minors may consent independently for certain services under state law, and confidentiality protections for adolescent reproductive and behavioral health care vary by jurisdiction.

4. Conflicts of Interest & Industry Relationships

Ambulatory pharmacists sit on P&T committees, write protocols, and select formulary agents — decisions with direct commercial consequence. The exam expects you to recognize and manage conflicts rather than merely avoid outright bribery.

Disclosure alone is insufficient when the conflict is direct and material — recusal is required. This is the most commonly missed nuance: candidates select "disclose the relationship" when the situation calls for disclosing and stepping out of the decision.

5. Conscientious Objection Without Patient Abandonment

A pharmacist may hold a personal moral objection to dispensing certain legally prescribed therapies. The professional constraint is that the objection may not become an obstacle to the patient's access:

• The objection should be declared in advance to the employer so coverage can be arranged, not raised at the counter.
• The patient must not be shamed, lectured, or interrogated about the indication.
• Care must be transferred promptly to another pharmacist or pharmacy that will fill the prescription, with the transfer arranged in a way that does not create a meaningful delay.
• The prescription and any related records must not be confiscated, withheld, or destroyed.

An answer choice describing refusal without an arranged alternative is always wrong.

6. Patient Advocacy as an Active Clinical Duty

BPS pairs ethics with patient advocacy in the same sub-topic, signaling that advocacy is an expected activity rather than a sentiment. In ambulatory practice it is largely concrete and financial:

• Cost-related nonadherence: Roughly one in five adults reports not filling a prescription because of cost. Advocacy means proactively asking about affordability — patients rarely volunteer it — then acting: therapeutic substitution to a covered agent, 90-day fills, pill-splitting where appropriate, manufacturer patient assistance programs, and Medicare Part D Extra Help / low-income subsidy screening.
• Prior authorization: Preparing the clinical justification, citing the guideline and documented failures of preferred agents, and pursuing the appeal when the initial request is denied. Abandoning therapy at first denial is a failure of advocacy.
• Formulary exceptions and step therapy: Documenting intolerance or contraindication to required first-line agents so the exception is defensible.
• Speaking for the patient in team settings: Raising goals-of-care misalignment when a team is intensifying therapy in a patient with limited life expectancy, or when treatment burden has outgrown likely benefit.

Ethics and Deprescribing

Deprescribing sits at the intersection of nonmaleficence and autonomy. Stopping a preventive medication in a patient whose remaining life expectancy is shorter than the drug's time to benefit is ethically sound care, not withholding treatment — but it requires an explicit conversation. Patients often interpret "we're stopping this" as "we're giving up on you," so frame deprescribing around reducing burden and harm, and document the shared decision.